drugset / Trial / NCT03046758
The Safety and Pharmacokinetics of Intraperitoneal Administration in Patients Undergoing Appendectomy for Uncomplicated Appendicitis
Phase 2
Completed
14 enrolled
Herlev Hospital
Barbara Juliane Holzknecht (Investigator) · collabJacob Rosenberg (Sponsor) · collabJohan Juhl Weisser (Partner, data analysis) · collabMagnus Arpi (Investigator) · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of this trial is to evaluate the safety of the intraperitoneal administration of the combination of fosfomycin, metronidazole, and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients undergoing surgery for uncomplicated appendicitis. Further, in a sub-trial the aim is to investigate the plasma concentrations of fosfomycin and metronidazole after intraperitoneal administration.
Timeline
- Start
- 2017-02-24
- Primary completion
- 2017-12-07
- Completion
- 2017-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosfomycin | Small molecule | 4 g | Intrathecal |
| Subject | Metronidazole | Small molecule | 1 g | Intrathecal |
| Subject | sargramostim | Protein / enzyme biologic | 50 ug | Intrathecal |